All In Biotech

Drug Trial Radar · NCT05723549

A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

A Randomized, Open-label, Single-Dose, Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1803 in Healthy Male Volunteers.

Last checked: Nov 20, 2026Latest source record: Sep 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Feb 2, 2023

Primary completion

Mar 20, 2023

Study completion Mar 20, 2023

Sponsor

Sponsor type
Industry
First posted
Feb 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, open-label, single-dose parallel study to evaluate the pharmacokinetics, safety and tolerability of HCP1803 in healthy male volunteers.

Conditions

  • Healthy

Interventions

  • HCP1803-3Drug

    Take it once per period

  • RLD2002Drug

    Take it once per period

  • HCP1904-1Drug

    Take it once per period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: 0~144hours
  2. AUC lastTime frame: 0~144hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yangji Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.